MYCOBACTERIOSIS: THE PAST AND PRESENT
Abstract
Non-tuberculous mycobacteria (NTM) are ubiquitous organisms, they are found everywhere in the vicinity. Humans are in everyday contact with these microorganisms. Although tuberculosis (TB) cases have been declining worldwide, there is a growing incidence of NTM infections. NTM may cause both asymptomatic infection and symptomatic disease in humans. The most common are pulmonary infections of varying severity. Accurate diagnosis is of crucial importance because the treatment medications may have serious adverse effects, among other things. The treatment of mycobacteriosis is not directly analogous to the treatment of tuberculosis. Empiric therapy is not recommended. In vitro susceptibility of many NTM does not correlate with clinical response to antimycobacterial drugs.
References
Adjemian J, Daniel-Wayman S, Ricotta E, Prevots DR. Epidemiology of Nontuberculous Mycobacteriosis. Semin Respir Crit Care Med. 2018;39(3):325-35. [CrossRef] [PubMed]
Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiares. Am J Respir Crit Care Med. 2012;185(8):881-6. [CrossRef] [PubMed]
Andréjak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontruberculous pul-monary mycobacteriosis in Denmark: incidence and prognostic factors. Am J respire Crit Care Med. 2010; 18(1):514-21. [CrossRef] [PubMed]
Ceron J, Pastor A, Sole A, Jorda C, Escriva J, Padilla J. Lung transplatation: Mycobacterium abscessus as a cause of graft dysfunction. Breath. 2007;3(3):291-5. [CrossRef]
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):1-36. [CrossRef] [PubMed]
Đurić O, Škodrić V, Vučinić V, Savić B. Oboljenja uzrokovana oportunističkim mikobakterijama-miko-bakterioze. Tuberkuloza. Savremena administracija. Beograd. 1996;366-406.
Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung decline in cystic fibrosis. J Cyst Fibros. 2010; 9(2):117-23. [CrossRef] [PubMed]
Global Tuberculosis Report. WHO. 2019.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. American Thoracic Society Document. An Official ATS/IDSA Statment, Diagnosis, Treatment, and Prevention of Nontuberculous Disea-ses. Am J Respir Crit Car Med. 2007;175(4):367-416. [CrossRef] [PubMed]
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. BTS Guidlines for the mena-gement of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(2):1-64. [CrossRef] [PubMed]
Hoefsloot W, van Ingen J, Magis-Escurra C, Reijers MH, van Soolingen D, Dekhuijzen RP, et al. Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations. J Infect. 2013;66:542-5. [CrossRef] [PubMed]
Honda JR, Knight V, Chan ED. Pathogenesis and risk factors for nontuberkulous mycobacterial lung disease. Clin Chest Med. 2015;36(1):1-11. [CrossRef] [PubMed]
http://www.bacterio.net/ mycobacterium.html
Jankovic M, Sabol I, Zmak L, Jankovic VK, Jakopovic M, Obrovac M, et al. Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. Int J Tuberc Lung Dis. 2016;20(7):934-40. [CrossRef] [PubMed]
Joint Tuberculosis Committee BTS. Menagment of opportunist mycobacterial infections: Joint Tubercu-losis Committee guidlines 1999. Thorax. 2000;55: 210-8. [CrossRef] [PubMed]
Katalinić –Janković V., Popović GS, Obrovac M, Cvetnić Ž, Alfirević T. Infekcije izazvane netuberku-loznim mikobakterijama. Lječnički vjesnik. 2007; 129(5):146-51. [PubMed]
Kim SY, Han SA, Kim DH, Koh WJ. Nontuberculous mycobacterial lung disease: ecology, microbiology, pathogenesis, and antibiotic resistance mechanisms. Precision and Future Medicine. 2017;1(3):99-114. [CrossRef]
Lin C, Russell C, Soll B, Chow D, Bamrah S, Brostrom R, et al. Increasing Prevalence of Nontuberculous Mycobacteria in Respiratory Specimens from US-Affiliated Pacific Island Juridictions. Center for Disease Control and Prevention, EID journal. 2018;24(3): 485-91. [CrossRef] [PubMed]
McGrath EE, McCabe J, Anderson PB. Guidelines on the diagnosis and treatment of pulmonary non-tuber-culous mycobacteria infection. Int J of Clin Pract. 2008;62(12):1947-55. [CrossRef] [PubMed]
Park SC, Kang MJ, Han CH, Lee SM, Kim CJ, Lee JM, et al. Prevalence, incidence, and mortality of non-tuberculous mycobacterial infection in Korea: a nationwide population-based study. BMC Pulm Med. 2019;19(1):140. [CrossRef] [PubMed]
Prevots DR, Marras KT. Epidemiology of Human Pulmonary Infection with NonTuberculous Mycobac-teria: A Review. Clin Chest Med. 2015;36(1):13-34. [CrossRef] [PubMed]
Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacte-ria: a review. Clin Chest Med. 2015;36(1):13-34. [CrossRef] [PubMed]
Procop GW, Church DL, Hall GS, Janda WM, Koneman EW, Schreckenberger PC, et al. Konemans Color Atlas and Textbook of Diagnostic Microbiology 7th edition. Chapter XIX. Philadelphia: Wolters Kluwer Health. 2017;1219-68.
Rivero-Lezcano OM, González-Cortés C, Mirsaeidi M. The unexplained increase of nontuberculous myco-bacteriosis. Int J Mycobacteriol. 2019;8:1-6. [CrossRef] [PubMed]
Sekulić S. Mikobakterioze. Plućne bolesti. Elit-Medica. Beograd. 2000;425-7.
The Research Committee of the British Thoracic Society. Pulmonary disease coused by M. malmoense in HIV negative patients: 5-yr follow-up of patients reciving standardied treatment. Eur Respir J. 2003;21 (3):478-82. [PubMed]
van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64(6):502-6. [CrossRef] [PubMed]
Van Ingen J, Turenne CY, Tortoli E, Wallace RJ Jr, Brown-Elliott BA. A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. Int J Syst Evol Microbiol. 2018;68(11): 3666-77. [CrossRef] [PubMed]
Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999.-2014. ATS journal. 2016;13(11):1951-5. [CrossRef] [PubMed]
Wallace RJ Jr, Cook JL, Glassroth J, Griffith DE, Olivier KN, Gordin F. An Official ATS/IDSA statement: diag-nosis and treatment of disease coused by non-tuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:1-25. [CrossRef]
Wang BY, Amolat MJ, Woo P, Brandwein-Gensler M. Atypical mycobacteriosis of the larynx: an unusual clinical presentation secondary to steroids inhalation. 2008;12(6):426-9. [CrossRef] [PubMed]
Wilson ML. Reducing the Global Burden of Myco-bacterial Infections One More Piece of the Puzzle. Am J Clin Pathol. 2008;130:849-52. [CrossRef] [PubMed]